An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regimen to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program

Trial Profile

An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regimen to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Nevirapine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANxITION
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2012 Results published in HIV Medicine.
    • 23 Feb 2012 Actual number of patients changed from 443 to 445 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top